Back to Results
First PageMeta Content
Prodrugs / Tamoxifen / Treatment of bipolar disorder / Breast cancer / Cancer / Endometrial cancer / Menopause / Oncotype DX / Breast cancer treatment / Medicine / Alkenes / AstraZeneca


Embargoed for Release: 7:30 a.m. CT, Dec. 5, 2012 Media Contact: Jeremy Moore
Add to Reading List

Document Date: 2012-12-05 07:30:22


Open Document

File Size: 83,25 KB

Share Result on Facebook

City

SAN ANTONIO / /

Company

AstraZeneca / /

Country

United Kingdom / /

/

Facility

University of Oxford / The University of Texas Health Science Center / Baylor College of Medicine / /

IndustryTerm

care for patients with breast cancer / Cancer Therapy / /

MedicalCondition

percent lower breast cancer / translational and clinical cancer / node-positive disease / endometrial cancer / positive breast cancer / Cancer Research U.K / approximately halving breast cancer / breast cancer / ER-positive breast cancer / /

Organization

European Union / U.K. Medical Research Council / American Association for Cancer Research / Baylor College of Medicine / United States Army / Clinical Trial Service Unit / University of Texas Health Science Center at San Antonio / University of Oxford / Cancer Therapy & Research Center / /

Person

Christina Davies / Jeremy Moore / /

/

Position

coordinator / /

PublishedMedium

Cancer Research / /

Technology

treating cancer / /

URL

www.sabcs.org / /

SocialTag